Lonza has officially expanded its accelerated DNA-to-Investigational New Drug (IND) platform, marking a significant milestone in the manufacturing of complex biologics. While the Swiss-based global manufacturing giant previously restricted its fast-track development pathway to traditional monoclonal antibodies (mAbs), the newly enhanced offering now encompasses a broader spectrum of sophisticated therapeutics, including bispecific antibodies, Fc-fusion proteins, and high-concentration drug product formulations.
The expansion is a direct response to the shifting landscape of biopharmaceuticals, where drug developers are increasingly favoring complex molecules that offer greater efficacy but present significant technical hurdles during the development and manufacturing phases. By applying its proprietary integrated development model to these more intricate formats, Lonza aims to help biopharmaceutical innovators shave months off their timelines, moving from initial DNA sequences to clinical testing with unprecedented speed.
“Earlier this year, we introduced our accelerated DNA-to-IND pathway for monoclonal antibodies,” said Gordon Bates, Head of Integrated Biologics at Lonza. “With this latest enhancement, we are extending those reduced timelines to more complex biotherapeutic formats… for which we are seeing growing demand as developers pursue increasingly advanced therapies.”
At the heart of this capability is the integration of Lonza’s new GS Ori Go vector technology—part of its well-established GS Gene Expression System—with over 30 years of manufacturing expertise. By utilizing prior knowledge and established development strategies at the earliest stage of the program, Lonza is positioning its clients to reduce technical risks and improve project predictability. The integrated program is designed to be highly efficient, with the capacity to deliver toxicology-grade drug substance in as little as three months and achieve IND readiness in approximately six months.
Beyond mere speed, the expanded offering addresses the practical realities of modern drug development. Lonza’s approach combines cell line development, analytical testing, and formulation development into a unified workflow. A critical component of this update is the earlier inclusion of high-concentration formulation development. As the industry moves toward more patient-friendly administration methods, such as subcutaneous injections, the ability to stabilize complex, high-concentration molecules early in the process is essential to ensure long-term scalability and successful clinical outcomes.
This development reflects a broader industry-wide push to shorten the time-to-market for innovative therapies. By aligning drug substance development with drug product manufacturing under a single coordinated framework, Lonza is providing a streamlined solution for companies navigating the complex transition from laboratory bench to human clinical trials. As developers continue to push the boundaries of molecular design, Lonza’s expanded platform serves as a vital infrastructure piece, ensuring that promising, next-generation biologics can reach patients faster and with greater manufacturing confidence.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
